Cargando…

Characterization of the 5-HT(2C) receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity

The 5-HT(2C) receptor agonist lorcaserin (Belviq®) has been Food and Drug Administration (FDA) approved for the treatment of obesity. The present study is a back translational investigation into the effect of 28-day lorcaserin treatment in a diet-induced obesity (DIO) model using male, Sprague–Dawle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Higgins, Guy A, Desnoyer, Jill, Van Niekerk, Annalise, Silenieks, Leo B, Lau, Winnie, Thevarkunnel, Sandy, Izhakova, Julia, DeLannoy, Ines AM, Fletcher, Paul J, DeLay, Josepha, Dobson, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317222/ https://www.ncbi.nlm.nih.gov/pubmed/25692009 http://dx.doi.org/10.1002/prp2.84

Ejemplares similares

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property
por: Higgins, Guy A., et al.
Publicado: (2021)

The 5-HT(2C) receptor agonist, lorcaserin, and the 5-HT(6) receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour
por: Higgs, Suzanne, et al.
Publicado: (2015)

Lorcaserin for weight management
por: Taylor, James R, et al.
Publicado: (2013)

Characterization of Amphetamine, Methylphenidate, Nicotine, and Atomoxetine on Measures of Attention, Impulsive Action, and Motivation in the Rat: Implications for Translational Research
por: Higgins, Guy A., et al.
Publicado: (2020)

Lorcaserin: A novel antiobesity drug
por: Brashier, Dick B. S., et al.
Publicado: (2014)

Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats
por: Gannon, Brenda M., et al.
Publicado: (2018)

The use of lorcaserin in the management of obesity: a critical appraisal
por: Bai, Bo, et al.
Publicado: (2010)

Lorcaserin improves glycemic control via a melanocortin neurocircuit
por: Burke, Luke K., et al.
Publicado: (2017)

Laboratory and Postmortem Diagnosis of Bovine Respiratory Disease
por: Caswell, Jeff L., et al.
Publicado: (2012)

Lorcaserin therapy for severe epilepsy of childhood onset: A case series
por: Tolete, Patricia, et al.
Publicado: (2018)

Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain
por: Di Giovanni, Giuseppe, et al.
Publicado: (2020)

Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
por: Hurt, Ryan T, et al.
Publicado: (2018)

Lorcaserin and metabolic disease: weight‐loss dependent and independent effects
por: Bays, H., et al.
Publicado: (2018)

Lorcaserin for the treatment of obesity? A closer look at its side effects
por: DiNicolantonio, James J, et al.
Publicado: (2014)

Lorcaserin and phentermine exert anti-obesity effects with modulation of the gut microbiota
por: Song, Eun-Ji, et al.
Publicado: (2023)

Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression
por: Wagner, Stefan, et al.
Publicado: (2022)

Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats
por: Price, Amanda E., et al.
Publicado: (2018)

RF24 | PSUN95 Defining Predictors of Weight Loss Response to Lorcaserin
por: Gugger, Aristea Sideri, et al.
Publicado: (2022)

Formulary Management of 2 New Agents: Lorcaserin and Phentermine/Topiramate for Weight Loss
por: Kelly, Elizabeth M., et al.
Publicado: (2013)

Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trials
por: Weissman, Neil J., et al.
Publicado: (2016)

Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
por: Jing, Muhan, et al.
Publicado: (2021)

Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial
por: Hurt, Ryan T., et al.
Publicado: (2022)

Coadministration of lorcaserin and phentermine for weight management: A 12‐week, randomized, pilot safety study
por: Smith, Steven R., et al.
Publicado: (2017)

Hypothesis: Amelioration of obesity‐induced cognitive dysfunction via a lorcaserin–betahistine combination treatment
por: dela Peña, Ike C., et al.
Publicado: (2022)

Gender and Monitoring the Response to HIV/AIDS Pandemic
por: DeLay, Paul
Publicado: (2004)

5-HT1A agonists, 5-HT3 antagonists and benzodiazepines : their comparative behavioural pharmacology /
Publicado: (1991)

A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss
por: Croghan, Ivana T., et al.
Publicado: (2016)

Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial
por: Johns, Sade E., et al.
Publicado: (2021)

Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats
por: Hummel, Jeff, et al.
Publicado: (2017)

Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings after 12 week-treatment: Randomized Sub-study
por: Rebello, Candida, et al.
Publicado: (2018)

Chronic Lorcaserin Treatment Reverses the Nicotine Withdrawal-Induced Disruptions to Behavior and Maturation in Developing Neurons in the Hippocampus of Rats
por: Zaniewska, Magdalena, et al.
Publicado: (2021)

Translating the promise of 5HT(4) receptor agonists for the treatment of depression
por: Murphy, Susannah E, et al.
Publicado: (2021)

CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
por: Capi, Matilde, et al.
Publicado: (2021)

Lorcaserin vs. Phentermine among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes
por: Elhag, Wahiba, et al.
Publicado: (2019)

Studying the Same-Gender Preference as a Defining Feature of Cultural Contexts
por: Bukowski, William M., et al.
Publicado: (2020)

Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis
por: Zeng, Hai, et al.
Publicado: (2019)

Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM‐DM studies
por: Fujioka, K., et al.
Publicado: (2019)

Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats
por: Yu, Haining, et al.
Publicado: (2017)

Anti-PTSD Effects of Hypidone Hydrochloride (YL-0919): A Novel Combined Selective 5-HT Reuptake Inhibitor/5-HT(1A) Receptor Partial Agonist/5-HT(6) Receptor Full Agonist
por: Liu, Wen-Gang, et al.
Publicado: (2021)

Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
por: Yempala, Thirumal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e8lmoraelvfn8u9t5rf4shplq8